These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8900340)

  • 1. Cost effectiveness of risk reduction: the managed care perspective.
    Shalowitz M; Heaton AH
    Am J Med; 1996 Oct; 101(4A):4A71S-74S; discussion 4A74S-75S. PubMed ID: 8900340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
    Kohli M; Attard C; Lam A; Huse D; Cook J; Bourgault C; Alemao E; Yin D; Marentette M
    Pharmacoeconomics; 2006; 24(8):815-30. PubMed ID: 16898850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical context: current concepts of coronary heart disease management.
    Jacobson TA
    Am J Med; 2001 Apr; 110 Suppl 6A():3S-11S. PubMed ID: 11311191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacoeconomic benefits of cholesterol reduction.
    Gonzalez ER
    Am J Manag Care; 1998 Feb; 4(2):223-30. PubMed ID: 10178493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Haldemann R; Lüscher TF; Szucs TD
    Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of HMG-CoA reductase inhibitors in the management of coronary artery disease: the problem of under-treatment.
    McCabe C
    Am J Cardiovasc Drugs; 2003; 3(3):179-91. PubMed ID: 14727930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA; Chaplin S
    Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
    Jacobson TA
    Am J Cardiol; 1996 Sep; 78(6A):32-41. PubMed ID: 8875973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
    Szucs TD; Lüscher TF; Gutzwiller F
    Schweiz Med Wochenschr; 1997 Nov; 127(44):1819-23. PubMed ID: 9446200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.
    Fonarow GC; French WJ; Parsons LS; Sun H; Malmgren JA
    Circulation; 2001 Jan; 103(1):38-44. PubMed ID: 11136683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain.
    Olry de Labry Lima A; Gimeno Ballester V; Sierra Sánchez JF; Matas Hoces A; González-Outón J; Alegre Del Rey EJ
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1027-1035. PubMed ID: 29937273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.